Nonalcoholic fatty liver disease (NAFLD), including its more severe manifestation,
nonalcoholic steatohepatitis (NASH), has a global prevalence of 20–25% and is a major …

Non-alcoholic fatty liver disease (NAFLD) has emerged as the most prevalent liver disease
in the world, yet there are still no approved pharmacological therapies to prevent or treat this …

One quarter of the global population is estimated to have nonalcoholic fatty liver disease
(NAFLD). The incidence of nonalcoholic steatohepatitis (NASH) is projected to increase by …

Background Although non-alcoholic fatty liver disease (NAFLD) is commonly associated
with obesity, it is increasingly being identified in non-obese individuals. We aimed to …

Description Nonalcoholic fatty liver disease (NAFLD) is well recognized as a leading
etiology for chronic liver disease, affecting> 25% of the US and global populations. Up to 1 …

Alcohol use and metabolic syndrome are highly prevalent in the population and frequently
co-exist. Both are implicated in a large range of health problems, including chronic liver …

Hepatocellular carcinoma (HCC) is a common cause of cancer‐related mortality and
morbidity worldwide. With the obesity pandemic, NAFLD‐related HCC is contributing to the …

Background Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver
disease worldwide. Many individuals have risk factors associated with NAFLD, but the …

中国人群的肝癌存在生存率低, 死亡率高的情况, 如何有效降低肝癌相关负担仍是中国公共卫生
和慢性病防控领域亟待解决的重大问题, 而肝癌人群筛查策略优化是值得持续探索的重要抓手和 …

Non-alcoholic steatohepatitis (NASH) develops from non-alcoholic fatty liver disease
(NAFLD). Currently, around 25% of the population is estimated to have NAFLD, and 25% of …